Journal of the American Academy of Dermatology
-
J. Am. Acad. Dermatol. · Sep 2010
Randomized Controlled Trial Multicenter Study Comparative StudyEfficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis.
The phase III randomized controlled evaluation of adalimumab every other week dosing in moderate to severe psoriasis trial (REVEAL) demonstrated adalimumab induced significant improvements and was well tolerated for patients with moderate to severe psoriasis. ⋯ Treatment of moderate to severe psoriasis with adalimumab led to consistent 75% or greater improvement in PASI score response rates across the majority of patient subgroups, with no significant differences in serious adverse events.